Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Imunon Inc IMNN

Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment... see more

Recent & Breaking News (NDAQ:IMNN)

Celsion Corporation to Ring the NASDAQ Stock Market Closing Bell on July 16, 2014

PR Newswire July 14, 2014

Celsion Corporation Completes Acquisition of EGEN, Inc.

PR Newswire June 20, 2014

Celsion Closes Second $5 Million Tranche under Loan Facility Agreement with Hercules Technology Growth Capital

PR Newswire June 10, 2014

Celsion Corporation to Acquire EGEN, Inc.

PR Newswire June 10, 2014

Celsion Advances Global Regulatory Efforts in Support of Pivotal Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer

PR Newswire May 21, 2014

Celsion Corporation Announces ThermoDox® Abstract Accepted at the 2014 American Society of Clinical Oncology 50th Annual Meeting

PR Newswire May 16, 2014

Celsion Corporation Reports First Quarter 2014 Financial Results and Provides Business Update

PR Newswire May 8, 2014

Celsion Corporation to Hold First Quarter 2014 Financial Results Conference Call on Thursday, May 8, 2014

PR Newswire May 1, 2014

Celsion Corporation Announces Updated Overall Survival Results from the HEAT Study of ThermoDox® in Primary Liver Cancer Presented at ECIO 2014

PR Newswire April 24, 2014

Celsion Announces ThermoDox® HCC Program to be discussed at the 2014 European Conference on Interventional Oncology in Berlin, Germany

PR Newswire April 10, 2014

Celsion's ThermoDox Plus High Intensity Focused Ultrasound Highlighted at 14th International Symposium on Therapeutic Ultrasound

PR Newswire April 9, 2014

Celsion Corporation Reports Year End 2013 Financial Results and Provides Business Update

PR Newswire March 13, 2014

Celsion Corporation to Hold Year-End 2013 Financial Results Conference Call on Thursday, March 13, 2014

PR Newswire March 6, 2014

Celsion Announces Positive Interim Data from Phase 2 DIGNITY Trial in Breast Cancer

PR Newswire February 27, 2014

Celsion Announces FDA Clearance of the OPTIMA Study - A Pivotal Phase III Trial of ThermoDox in Primary Liver Cancer

PR Newswire February 24, 2014

Five Star Equities Issues New Research Reports on CECO, CLSN, GAME and RSOL

Accesswire January 29, 2014

Celsion Corporation Announces Updated Overall Survival Results from Phase III HEAT Study of ThermoDox® in Primary Liver Cancer

PR Newswire January 27, 2014

Celsion Corporation Initiates Development Program for Glioblastoma Brain Tumors with ThermoDox® and HIFU

PR Newswire January 21, 2014

Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering

PR Newswire January 15, 2014

Five Star Equities Issues New Research Reports on CLSN, CNDO, OMCL and XOMA

Accesswire December 16, 2013